Amelioration of dyslipidemia in salsalate-treated HHTg rats was associated with reduced hepatic expression of Fasn (p < 0.001) and Srebp1 (p < 0.001) genes coding for lipogenic enzyme and lipogenic transcription factor, respectively (Figure 4). This evidence concerns the gene SREBF1 and metabolic syndrome.